GSK, Exelixis Expedite Review Of Lead MET Inhibitor
This article was originally published in The Pink Sheet Daily
Executive Summary
Exelixis has agreed to let its partner review XL880 ahead of proof-of-concept to determine whether to pursue commercialization.